The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …

Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1· 8
million people are diagnosed with lung cancer, and 1· 6 million people die as a result of the …

Background Osimertinib is an oral, third-generation, irreversible epidermal growth factor
receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI …

Background Osimertinib is an epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR-TKI) that is selective for both EGFR-TKI sensitizing and T790M resistance mutations …

Precision oncology seeks to leverage molecular information about cancer to improve patient
outcomes. Tissue biopsy samples are widely used to characterize tumours but are limited by …

Background Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor.
We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor …

Lung cancer remains a leading cause of cancer related mortality worldwide. Despite
numerous advances in treatments over the past decade, non-small cell lung cancer …

The biggest hurdle to targeted cancer therapy is the inevitable emergence of drug
resistance. Tumor cells employ different mechanisms to resist the targeting agent. Most …

Summary Background The irreversible ErbB family blocker afatinib and the reversible EGFR
tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation …

The era of personalized medicine for advanced-stage non-small-cell lung cancer (NSCLC)
began when biomarker-based evidence of molecular pathway and/or oncogene addiction of …